A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

​ Conditions: Multiple Myeloma (MM)

Interventions: Drug: Teclistamab; Drug: Talquetamab; Drug: Daratumumab (Subcutaneously); Drug: Lenalidomide

Sponsors: Polish Myeloma Consortium; Medical Research Agency, Poland; Johnson & Johnson

Not yet recruiting Conditions: Multiple Myeloma (MM)
Interventions: Drug: Teclistamab; Drug: Talquetamab; Drug: Daratumumab (Subcutaneously); Drug: Lenalidomide
Sponsors: Polish Myeloma Consortium; Medical Research Agency, Poland; Johnson & Johnson
Not yet recruiting